MedPage Today on MSN

Bimekizumab Safety Holds Up in Long-Term Data

Pooled data from PsA and axSpA extension studies provide early reassurance ...
rmdopen.bmj

Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studies

Objective To present updated integrated safety analyses of bimekizumab in patients with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). Methods Safety data pooled from six phase IIb/III ...
Medscape

Will New Polymyalgia Rheumatica Treatments Lessen Need for ‘Improvisation’?

As IL-6 inhibition comes into practice for PMR, research advances on other therapeutic mechanisms of action, from IL-17 to ...
Rheumatology Advisor

Expert Roundtable: Cutaneous Lupus Erythematosus

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.
Le Lézard

BIMZELX®?(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...